Pulmozyme for Sjogren's Associated Cough

Withdrawn before enrolling · Phase 1

Conditions studied: Sjogren's Syndrome, Cough

In brief

Patients with Sjogren's disease have destruction of the mucus secreting cells in the airway. This manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. This study is aimed at determining whether the regular use of Pulmozyme will result in decreased cough and improved quality of life.

Key facts

Study ID

NCT01357447

Run by

UConn Health

People needed

0

Starts

2011-05-01

Expected to finish

2012-03-01

Last updated by the study team

2020-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or above with primary Sjogren's disease (as defined by the American European Consensus Group Criteria), and complaint of chronic cough.
• Able to give consent and anticipated ability to adhere to the study procedures.

You may not qualify if…

• Diagnosis of COPD, emphysema, asthma, chronic bronchitis, other clinically significant lung disease that is likely to cause cough. Interstitial lung disease associated with Sjogren's is not excluded.
• Cigarette use of greater than 20 pack years or regular use within 6 months
• Allergy or intolerance to Pulmozyme.
• Acute respiratory infection or other acute respiratory illness during the prior month.
• LCQ greater than 17 and VAS less than 3 cm at baseline (Visit 1).
• Pregnancy or breast feeding.

Where it is running

• University of CT Health Center — Farmington, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.